Cidara Therapeutics price target raised to $145 from $137 at RBC Capital

RBC Capital raised the firm’s price target on Cidara Therapeutics (CDTX) to $145 from $137 and keeps an Outperform rating on the shares. The company’s CD388 Phase 3 enrollment is already halfway done and on pace for completion in December, potentially enabling readout as early as Q3 should flu event rates fall in line with their projections, the analyst tells investors in a research note. The stock has room for additional meaningful upside, the firm added.